65,437 trials
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Primary Outcome Measure: Percentage of Subjects Improved Global Response Assessment Scale — 4; 3 Participants — p=0.317
Labor, Induced · Cervix Uteri-Diseases
Primary: Number of Participants With Hospital Stay Longer Than 48 Hours — 89; 152 Participants
Healthy
Primary: Change in Motivation From Baseline at 12 Weeks. — 0.30; 0.48; 0.40; 0.43 Units on a scale
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance
Heart Failure · Atrial Fibrillation
Primary: Number of Participants With an Identified Dysrhythmia on Baseline ECG Recording — 25; 35 Participants
Pharmacokinetics · Safety Issues
Primary: Peak Serum Concentration of Bevacizumab (Cmax) — 22144.83; 21540; 22566.67 ng/ml — p=0.9766
Fever
Primary: Accuracy of Masimo RAD-GT Temperature Measurments — -0.24; 0.85; 0.09 Degrees Celsius
Healthy
Primary: Area Under the Concentration-time Curve of BI 730357 Over the Time Interval From 0 to Infinity (Dose Normalized). — NA; NA mmol*h/L/kg
Cervical Dysplasia · Cervical High Grade Squamous Intraepithelial Lesion · HSIL
Primary: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples — 22.5; 11.1 percentage of…
Hot Flashes
Primary: Change From Baseline to Week 12 in The Weekly General Hot Flash Score — -12.19; -26.51 score on a scale — p=<0.001
Chronic Kidney Disease · Metabolic Acidosis
Primary: Change in Brachial Artery Flow Mediated Dilation — 3.99; 3.78; 4.25; 4.43 percentage
Pain Management
Primary: Pain Following Dilator Placement — 64; 60.5 units on a scale
Head and Neck Squamous Cell Carcinoma
Primary: Locoregional Control — 17 participants
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Lung Adenocarcinoma · Lung Neoplasms
Primary: Progression Free Survival 1 (PFS 1) for ALL Participants Who Started Osimertinib on Trial Until First Progression of Disease or Clinical Progression, or Death Any Cause…